Gedeon Richter, Forest tout promising results from antipsychotic Ph3

Investigators are reporting promising preliminary top-line results from a late-stage study of an experimental antipsychotic being studied by Hungary's Gedeon Richter and Forest Laboratories ($FRX). Shares of Gedeon Richter climbed a bit on the news.

Bipolar patients suffering from acute mania reported progress as early as 5 days after beginning treatment with cariprazine (RGH-188). Cariprazine is also being investigated in clinical studies for patients with schizophrenia, bipolar depression, and as an adjunct treatment for major depression.

"As we continue to move forward with the development of this important compound, these positive phase III results further demonstrate the opportunity for cariprazine as a potential new treatment option for patients suffering from bipolar mania" said Marco Taglietti, senior VP of R&D at the Forest Research Institute.

"In the three consecutive positive trials, statistically significant results demonstrated improvement in symptoms compared to placebo, importantly including the low dose range arm," noted Gedeon's Zsolt Szombathelyi.

- here's the press release
- get the story from Bloomberg

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.